FindTrial
Sign In

Mesothelin Expression

DEVICE3 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Adenocarcinoma of LungAdenocarcinoma, PancreaticCholangiocarcinoma, ExtrahepaticEpithelioid MesotheliomaLung CancerNeoplasmsNeoplasms With Mesothelin ExpressionNon-Small Cell Lung Cancer

Phase 1

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
CompletedNCT02810418
National Cancer Institute (NCI)Neoplasms, Pancreatic Neoplasms
Start: 2016-08-03End: 2021-06-22Updated: 2022-03-15
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
CompletedNCT04034238
National Cancer Institute (NCI)Adenocarcinoma, Pancreatic, Cholangiocarcinoma, Extrahepatic, Epithelioid Mesothelioma +1
Start: 2019-08-29End: 2021-11-19Updated: 2023-08-01

Phase 2

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
TerminatedNCT04027946
National Cancer Institute (NCI)Adenocarcinoma of Lung, Lung Cancer, Non-Small Cell Lung Cancer
Start: 2019-09-11End: 2023-12-22Updated: 2024-04-16

Related Papers

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers
Frontiers in Oncology2024-04-195 citations
Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib.
Journal of Clinical Oncology2023-06-01
Systemic immune changes accompany combination treatment with immunotoxin <scp>LMB</scp>‐100 and nab‐paclitaxel
Cancer Medicine2022-10-089 citations
Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.
Journal of Clinical Oncology2021-05-204 citations
Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.
Journal of Clinical Oncology2021-01-204 citations
Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.
Journal of Clinical Oncology2020-05-202 citations
A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer.
Journal of Clinical Oncology2019-01-293 citations